| Name | Title | Contact Details |
|---|
Access Case Management Services of Georg is a Savannah, GA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Illinois Knights Templar Home is a Paxton, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Mr. Gallagher is Senior Vice President & Chief Financial Officer at RRD International, LLC. Mr. Gallagher provides strategic, operational, and financial leadership to RRD. His primary responsibilities are planning, implementing, managing, and controlling all financial-related activities including the development of financial and operational strategies. Mr. Gallagher has over 20 years of finance experience in the biopharma industry with both multi-national corporations and commercial-stage public biotechnology companies. He has an extensive background in all areas of corporate controllership, including financial planning & analysis, cost control, management accounting, corporate administration, and systems implementation. He has supported all aspects of product development and commercialization, including the negotiation and execution of licensing and collaboration agreements with major pharma partners. Mr. Gallagher served previously as Vice President of Finance for Optimer Pharmaceuticals and, prior to that, as Senior Director of Finance and Corporate Controller for Adolor Corporation. He had a central role in the sale of both companies. Mr. Gallagher spent the first 10 years of his career with Therakos, Inc. (a Johnson & Johnson company) and Merck & Co., Inc. He received his BS in Finance from The Pennsylvania State University and is an active Certified Management Accountant (CMA).
StemCells, Inc., a biopharmaceutical company, engages in the research, development, and commercialization of cell-based therapeutics and tools for use in stem cell-based research and drug discovery primarily in the United States. Its lead therapeutic product candidate, HuCNS-SC cells (purified human neural stem cells), is in development as a potential treatment for a range of central nervous system disorders. The company has conducted a Phase I clinical trial in Pelizaeus-Merzbacher disease, a fatal myelination disorder in children. It is also conducting a Phase I/II clinical trial in chronic spinal cord injury; and has initiated a Phase I/II clinical trial in dry age-related macular degeneration, as well as is pursuing preclinical studies in Alzheimer’s disease. In addition, the company markets a rage of proprietary cell culture products, research grade human cells, and antibody reagents under the SC Proven brand. The proprietary cell culture products include iSTEM, GS1-R, GS2-M, RHB-A, RHB-Basal, NDiff227, NDiff N2, and NDiff N27 supplements, as well as HEScGRO and ESGRO Complete; and antibody reagents comprise STEM24, STEM101, STEM121, and STEM123, which can be used for cell detection, isolation, and characterization. Further, StemCells is involved in developing and commercializing applications of its technologies to enable stem cell-based research. The company sells its tools and technologies products to researchers at academic institutions, pharmaceutical and biotechnology companies, and government laboratories. StemCells, Inc. was founded in 1988 and is headquartered in Newark, California.
Arrow International (Teleflex Incorporated) is one of the leading companies in Healthcare, Pharmaceuticals, and Biotech industry. Arrow International (Teleflex Incorporated) is based in Reading, PA. You can find more information on Arrow International (Teleflex Incorporated) at www.arrowintl.com